Literature DB >> 26939159

LYMPHODYSPLASIA AND KRAS MUTATION: A CASE REPORT AND LITERATURE REVIEW.

G Morcaldi, T Bellini, C Rossi, M Maghnie, F Boccardo, E Bonioli, C Bellini.   

Abstract

Cardio-facio-cutaneous (CFC) syndrome is a very rare and sporadic disease whose characteristics include dysmorphic facial appearance, ectodermal abnormalities, cardiac abnormalities, growth retardation and neurodevelopmental delay. This syndrome is classified as one of the RAS syndromes which are caused by altered signal transduction of the RAS/MAPK (mitogen activated protein kinase) pathway due to the mutation of genes including BRAF, MEK1/2, HRAS and KRAS. Other RAS syndromes, such as Costello syndrome and Noonan syndrome, share clinical features with CFC. Moreover, patients with the same clinical phenotype may have different molecular diagnoses. Clinical diagnosis is the starting pointfor correct classification. We describe the clinical data of one case of CFC syndrome, genetically determined by KRAS mutation, that involved chylothorax, lymphedema, sinus pericranii, craniosynostosis, and seizures. This is the second case report of the literature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26939159

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  6 in total

1.  ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

Authors:  Dong Li; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Christoph Seiler; Erin Pinto; Leticia S Matsuoka; Mark R Battig; Elizabeth J Bhoj; Tara L Wenger; Lifeng Tian; Nora Robinson; Tiancheng Wang; Yichuan Liu; Brant M Weinstein; Matthew Swift; Hyun Min Jung; Courtney N Kaminski; Rosetta Chiavacci; Jonathan A Perkins; Michael A Levine; Patrick M A Sleiman; Patricia J Hicks; Janet T Strausbaugh; Jean B Belasco; Yoav Dori; Hakon Hakonarson
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

Review 2.  Systematic literature review of lymphatic imaging-guided procedural management of Noonan syndrome.

Authors:  Taylor Paul Cox; Christopher James Vance; Sarah K Daley; Cristobal Papendieck; Hugh McGregor; Philip Kuo; Marlys H Witte
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2022-05-10

Review 3.  Lymphatic Abnormalities in Noonan Syndrome Spectrum Disorders: A Systematic Review.

Authors:  Julia Sleutjes; Lotte Kleimeier; Erika Leenders; Willemijn Klein; Jos Draaisma
Journal:  Mol Syndromol       Date:  2021-09-10

4.  Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly.

Authors:  Dong Li; Tara L Wenger; Christoph Seiler; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Elizabeth Bhoj; Lifeng Tian; Misha Rosenbach; Yichuan Liu; Nora Robinson; Mechenzie Behr; Rosetta Chiavacci; Cuiping Hou; Tiancheng Wang; Marina Bakay; Renata Pellegrino da Silva; Jonathan A Perkins; Patrick Sleiman; Michael A Levine; Patricia J Hicks; Maxim Itkin; Yoav Dori; Hakon Hakonarson
Journal:  Hum Mol Genet       Date:  2018-09-15       Impact factor: 6.150

5.  Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib.

Authors:  Harish P Janardhan; Karen Dresser; Lloyd Hutchinson; Chinmay M Trivedi
Journal:  JCI Insight       Date:  2022-09-08

6.  Parkes Weber syndrome with lymphedema caused by a somatic KRAS variant.

Authors:  Whitney Eng; Christopher L Sudduth; Dennis J Konczyk; Patrick J Smits; Amir H Taghinia; Steven J Fishman; Ahmad Alomari; Denise M Adams; Arin K Greene
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.